Real-world use of different pembrolizumab regimens (3 weekly versus 6 weekly) in non-small cell lung cancer (NSCLC) patients. (March 2022) - Osborne, Lucy; Ortega-Franco, Ana; Hodgson, Clare; Pearce, Mark; Moss, Anna; Lindsay, Colin; Hughes, Sarah; Taylor, Paul; Califano, Raffaele; Rafee, Shereen; Gomes, Fabio; Summers, Yvonne; et al.